## CLAIMS

What is claimed and desired to be secured by Letters Patent is as follows:

- 1. A growth promoting implant for placement in a solid bio-accessible form under the skin of an animal said implant comprising:
  - a) a growth stimulating agent; and
  - b) a supplemental agent that cooperates with said growth stimulating agent to promote growth.
- 2. The implant according to Claim 1 wherein:
  - a) said growth stimulating agent is selected from the group consisting of trembolone acetate, estradiol, estradiol benzoate, zeranol, testosterone propionate, progesterone, mixtures and bioeffective derivatives thereof.
- 3. The implant according to Claim 1 wherein:
  - a) said supplemental agent is chosen from the group consisting of parasiticides, estrus suppressing compositions, antibiotics, somatotropins, gonadotropins and mixtures thereof.



- 4. The implant according to Claim 3 wherein:
  - a) at least one of said agents includes both an immediate release component and a time delayed component.
- 5. The implant according to Claim 3 wherein:
  - a) said supplemental agent is a parasiticide.
- 6. The implant according to Claim 5 wherein:
  - a) said parasiticide is chosen from the group consisting essentially of ivermectin, abamectin, doramectin, moxidectin, milbemycin oxime, fenbendazole, and oxfendazole.
- 7. The implant according to Claim 5 wherein:
  - a) said parasiticide is present in both an immediate release portion and a time delayed portion.
- 8. The implant according to Claim 1 wherein:
  - a) said growth stimulating agent is estradiol benzoate in a dosage amount in the range from about 5 to 50 milligrams per implant; and

- b) said supplemental agent is ivermectin in a dosage amount in the range from about 100 to 500 milligrams per implant.
- 9. The implant according to Claim 1 wherein:
  - a) said growth stimulating agent and said supplemental agent are mixed in at least one pellet of said implant.
- 10. The implant according to Claim 1 wherein:
  - a) said growth stimulating agent and said supplemental agent are in separate pellets of said implant.
- 11. The implant according to Clarm 3 wherein:
  - a) said estrus suppressing composition is chosen from the group consisting essentially of melengestrol acetate, norgestomet, other progestins, mixtures and bio-effective derivatives thereof.
- 12. The implant according to Claim 11 wherein:
  - a) said growth stimulating agent is trenbolone acetate in a dosage amount in the range from about 20 to 400 milligrams per implant; and

b) said estrus suppressing composition is melengestrol acetate in a dosage amount in the range from about 10 to 100 milligrams per implant.

## 13. The implant according to Claim 3 wherein:

- a) said antibiotic is selected from the group consisting essentially of tylosin tartrate, tylosin, oxytetracycline, tilmicosin phosphate, ceftiofur hydrochloride, ceftiofur sodium, sulfadimethoxine, mixtures and bio-effective derivatives thereof.
- 14. The implant according to Claim 13 wherein:
  - a) said growth stimulating agent is estradiol in a dosage amount in the range from about 5 to 50 milligrams per implant; and
  - b) said antibiotic is tilmicosin phosphate in a dosage amount in the range from about 500 to 1500 milligrams per implant.
- 15. The implant according to Claim 3 wherein:
  - a) said supplemental agent is a somatotropin selected from the group consisting essentially of bovine

somatotropin and porcine somatotropin, mixtures and bio-effective derivatives thereof.

- 16. The implant according to Claim 15 wherein:
  - a) said growth stimulating agent is estradiol and said supplemental agent is bovine somatotropin.
- 17. The implant according to Claim 3 wherein:
  - a) said supplemental agent is a gonadotropin selected from the group consisting essentially of luteinizing hormone, follicle stimulating hormone, gonadotropin releasing hormone, commercial analogs thereof, mixtures and bio-effective derivatives thereof.
- 18. The implant according to Claim 17 wherein:
  - a) said growth stimulating agent is estradiol; and
  - b) said supplemental agent is luteinizing hormone.
- 19. A method for providing enhanced physiological growth in an animal; said method comprising:
  - a) providing an implanter apparatus for implanting pellets in an animal through the bore of a

4 1 1 1 3

hypodermic needle which is operably coupled to a pellet magazine;

- b) loading the pellet magazine with a pelletized implant including a growth stimulating agent dose and a supplemental agent dose;
- c) inserting the hypodermic needle under the skin of the animal and injecting the implant into the animal; and
- d) withdrawing the hypodermic needle from under the skin of the animal so as to leave the implant beneath the skin.
- 20. The method according to Claim 19 including the step of
  - a) selecting said supplemental agent from the group consisting essentially of parasiticides, antibiotics, estrus suppressing compounds, somatotropins, gonadotropins, mixtures and bioeffective derivatives thereof.
- 21. The method according to Claim 20 including the steps of:
  - a) selecting a parasiticide as said supplemental agent from the group consisting essentially of ivermectin, avermectin, abamectin, doramectin,

moxidectin, oxime, oxfendazole, milbemycin, fenbendazole, lufenuron, mixtures and bio-effective derivatives thereof; and

- b) selecting the growth stimulating agent dose from the group consisting essentially of trenbolone acetate, estradiol, estradiol benzoate, zeranol, testosterone propionate, and progesterone.
- 22. The method according to Claim 21 including the step of selecting ivermectin as the supplemental agent.
- 23. The method according to Claim 22 including the step of selecting estradiol as the growth stimulating agent.
- 24. The method according to claim 21 including providing the step of a plurality of discrete pellets.
- 25. The method according to claim 21 including the step of providing at least one discrete parasiticide agent dose and at lease one discrete growth stimulating agent dose.
- 26. In a method of administering a subcutaneous implant to an animal, the improvement comprising:

- a) including a growth stimulating agent and a supplemental agent in a single injection.
- 27. In an implant adapted for subcutaneous implantation in an animal by an implanter apparatus through the bore of a hypodermic needle which is coupled to a pellet magazine, the improvement comprising:
  - a) said implant including at least one pellet sized and shaped to be implanted through the needle and positioned in the magazine for selective alignment of the implant with the needle; and
  - b) said implant including a parasiticide agent dose and a growth stimulating agent dose.
- 28. The implant according to Claim 27 wherein the parasiticide agent dose includes a composition selected from the group consisting of an avermectin, milbemycin, oxime, fenbendazole, oxfendazole, lufenuron, mixtures and bio-effective derivatives thereof.
- 29. The implant according to Claim 27 wherein the parasiticide agent comprises ivermectin.

- 30. The implant according to Claim 27 wherein the growth stimulating agent dose comprise compositions selected from the group consisting of trenbolone acetate, estradiol, estradiol benzoate, zeranol, testosterone propionate, and progesterone.
- 31. The implant according to Claim 28 wherein said parasiticide agent is present in:
  - a) an immediate release agent pellet including a disintegration agent; and
  - b) an extended release agent pellet including a bioerodible matrix.
- 32. An implant for subcutaneous implantation in an animal comprising:
  - a) at least one discrete parasiticidal agent pellet dose; and
  - b) at least one discrete growth stimulating agent pellet dose; all of said pellets being combined in a single unit for implantation side by side into. the same site.

